{
    "clinical_study": {
        "@rank": "94136", 
        "brief_summary": {
            "textblock": "To provide emergency access to OBI-1 for patients with Acquired Hemophilia and a serious\n      bleeding episode who do not have access to an active clinical study site associated with the\n      OBI-1-301 study."
        }, 
        "brief_title": "Expanded Access to B-Domain Deleted Recombinant Porcine Factor VIII (OBI-1) in the Treatment of Acquired Hemophilia A Due to Factor VIII Inhibitory Auto-antibodies", 
        "condition": "Acquired Hemophilia A", 
        "condition_browse": {
            "mesh_term": "Hemophilia A"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Written informed consent from participant or their legal representative.\n\n          -  Participants with acquired hemophilia with autoimmune inhibitors to human factor\n             VIII.\n\n          -  Has a serious bleeding episode, as documented by the investigator.\n\n          -  Be willing and able to follow all instructions and attend all study visits.\n\n          -  Participants taking anti-thrombotics may be included depending on the time elapsed\n             since taking such medications.\n\n          -  Life expectancy of at least 90 days prior to the onset of the bleeding episode.\n\n        Exclusion Criteria:\n\n          -  Hemodynamically unstable after blood transfusion, fluid resuscitation and\n             pharmacologic or volume replacement pressor therapy.\n\n          -  Has an established reason for bleeding that is not correctable.\n\n          -  Bleeding episode assessed likely to resolve on its own if left untreated.\n\n          -  Anti-OBI-1 inhibitor that exceeds 20 BU (prospectively or retrospectively).\n\n          -  Subsequent bleeding episode at the site of the initial qualifying bleeding episode\n             within 2 weeks following the final OBI-1 dose for the initial qualifying bleeding\n             episode, or subsequent bleeding episode at a different site than the initial\n             qualifying bleeding episode within 1 week following the final OBI-1 dose for the\n             initial qualifying bleeding episode will not be considered \"new\" qualifying bleeding\n             episodes.\n\n          -  Prior history of bleeding disorder other than acquired hemophilia.\n\n          -  Known major sensitivity (anaphylactoid reactions) to pig or hamster products.\n\n          -  Use of hemophilia medication within 3 to 6 (depending on medication) hours prior to\n             OBI-1 administration.\n\n          -  Participation in any other clinical study within 30 days of the first OBI 1\n             treatment.\n\n          -  Anticipated need for treatment or device during the study that may interfere with the\n             evaluation.\n\n          -  Abnormal baseline findings\n\n          -  Inability or unwillingness to comply with the study design, protocol requirements, or\n             the follow-up procedures."
            }, 
            "gender": "Both", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "firstreceived_date": "October 21, 2013", 
        "id_info": {
            "nct_id": "NCT01968655", 
            "org_study_id": "OBI-1-301a"
        }, 
        "intervention": {
            "intervention_name": "OBI-1", 
            "intervention_type": "Biological", 
            "other_name": "B-Domain Deleted Recombinant Porcine Factor VIII"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Antibodies", 
                "Autoantibodies", 
                "Factor VIII"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": "Factor VIII Inhibitory Auto-antibodies", 
        "lastchanged_date": "October 21, 2013", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Bethesda", 
                        "country": "United States", 
                        "state": "Maryland", 
                        "zip": "20892"
                    }, 
                    "name": "National Institutes of Health Warren G. Magnuson Clinical Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Boston", 
                        "country": "United States", 
                        "state": "Massachusetts", 
                        "zip": "02111"
                    }, 
                    "name": "Tufts Medical Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Hershey", 
                        "country": "United States", 
                        "state": "Pennsylvania", 
                        "zip": "17033"
                    }, 
                    "name": "Penn State"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Nashville", 
                        "country": "United States", 
                        "state": "Tennessee", 
                        "zip": "37232"
                    }, 
                    "name": "Vanderbilt Hemostasis/Hemophilia Clinic"
                }
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "official_title": "Expanded Access to B-Domain Deleted Recombinant Porcine Factor VIII (OBI-1) in the Treatment of Acquired Hemophilia A Due to Factor VIII Inhibitory Auto-antibodies", 
        "overall_official": {
            "affiliation": "Baxter Healthcare Corporation", 
            "last_name": "Heinrich Farin, MD", 
            "role": "Study Director"
        }, 
        "overall_status": "No longer available", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "N/A", 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01968655"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Baxter Healthcare Corporation", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Baxter Healthcare Corporation", 
                "agency_class": "Industry"
            }
        }, 
        "study_design": "N/A", 
        "study_type": "Expanded Access", 
        "verification_date": "October 2013"
    }
}